Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the UK.
| Revenue (TTM) | $-3.60M |
| Gross Profit (TTM) | 0 |
| EBITDA | $-21.12M |
| Operating Margin | 0.00% |
| Return on Equity | -924.00% |
| Return on Assets | -116.00% |
| Revenue/Share (TTM) | $-0.02 |
| Book Value | $0.08 |
| Price-to-Book | 18.53 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -5.98 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $127.25M |
| Float | $65.73M |
| % Insiders | 43.95% |
| % Institutions | 3.14% |
Volatility is currently contracting